Hematology Customer Service Advisor
About the job
- Previous customer service experience in a related industry or technical environment.
- Familiarity with hematology products or the healthcare industry is a plus.
- Strong organizational skills and attention to detail.
- Ability to work independently and in team settings.
- Excellent communication and problem-solving skills.
- Ability to work at a computer for extended periods.
- Ability to lift and handle materials weighing 5–20 lbs.
- Ability to work in an extended mode of transportation.
- Follow the assigned team schedule reliably and manage time effectively, including working extended hours when necessary.
- Comply with Standard Operating Procedures and Work Instructions in ComplianceWire, including completing all assigned compliance training.
- Gain familiarity with Standard Operating Procedures of other departments within the division to support interdepartmental collaboration.
- Use Enterprise Resource Planning systems to process new and replacement customer orders accurately.
- Proofread and validate orders processed by teammates.
- Initiate complaints and coordinate with technical support within 24 hours of issue receipt.
- Respond promptly to general customer inquiries and provide updated production schedules.
- Learn multiple departmental functions and increase independence in daily tasks as part of continuous improvement.
- Handle multiple tasks and adapt to changing workload priorities within expected boundaries.
- Communicate with internal departments and customers.
- Support other departments as needed and complete additional assigned duties.
- Use Microsoft Office Suite to perform daily responsibilities.
- Order lunches for events and set up and tear down conference rooms.
- Meet quality standards in daily work and demonstrate company values in all activities.
- Work onsite during standard business hours, with occasional schedule variation based on production needs.
- High School Diploma or GED equivalent.
- Familiarity with hematology products or the healthcare industry.
About the company
Bio-Techne makes and sells life-science tools such as purified proteins, cytokines, growth factors, antibodies, immunoassays, and reagent solutions, along with ProteinSimple analytics and cell/gene therapy workflow technologies. Researchers use these products to produce, analyze, and quantify biomolecules and to carry out assays and workflow steps in cancer, immunology, and regenerative medicine. The company differentiates itself with a broad, integrated catalog and end-to-end support—from raw proteins to analytical solutions—delivered to a global customer base. Its goal is to be a leading provider of life-science tools that speed up discovery and development in healthcare and biology.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Minneapolis, Minnesota
Founded
1981
Get referred to Bio-Techne
See people who can refer or advise you
Simplify's Take
What believers are saying
- Bio-Techne shareholders approved Merck’s acquisition on September 23, 2026, clearing a major hurdle.
- August 12, 2026 results showed 3% organic fourth-quarter growth and 310-basis-point margin expansion.
- July 2026 AI-engineered proteins expand cell-therapy demand and strengthen advanced culture workflows.
What critics are saying
- Merck’s $73-per-share acquisition closes late 2026 or early 2027, ending independence.
- Fiscal 2026 revenue stayed flat at $1.2 billion, exposing weak organic demand.
- Restructuring through fiscal 2027 and Merck integration threaten roles, autonomy, and duplicated functions.
What makes Bio-Techne unique
- Bio-Techne’s 50-year protein catalog still anchors customer loyalty across research workflows.
- ProteinSimple, RNAscope, and spatial biology create sticky, integrated tools across discovery.
- The Düsseldorf Customer Experience Center deepens European adoption of Bio-Techne workflows.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Short-term Disability
Long-term Disability
Pet Insurance
Legal Services
401(k) Company Match
Company Equity
Professional Development Budget
Paid Vacation
Paid Sick Leave
Paid Holidays
Parental Leave
Unlimited Paid Time Off
Hybrid Work Options
Employee Stock Purchase Plan
Growth & Insights and Company News
6 month growth
↑ 2%1 year growth
↑ 2%2 year growth
↑ 2%Bio-Techne Corporation, a Minneapolis-based life science company valued at $11.4 billion, has significantly outperformed the Nasdaq Composite in recent months. The stock gained 28.9% over the past three months, compared to the Nasdaq's 5.3% rise during the same period. Year-to-date, Bio-Techne shares climbed 23.3%, whilst advancing 37% over the past 52 years, surpassing the Nasdaq's YTD gains of 15.9% and annual returns of 19.3%. The company reported mixed financial results, with full-year sales remaining flat at $1.2 billion due to sluggish biotech funding and uneven biopharma demand. However, disciplined cost controls and operational efficiencies improved GAAP operating margins and net earnings. In its Q4 results announced in August, Bio-Techne met earnings expectations with adjusted EPS of $0.52, whilst revenue of $321.2 million exceeded Wall Street forecasts of $317.2 million.
Bio-Techne opens new Customer Experience Center in Düsseldorf to accelerate scientific discovery and customer collaboration. Sep 22, 2026, 09:00 ET * New flagship facility provides hands-on access to Bio-Techne technologies, workflows and scientific expertise * Regional hub will support researchers and organizations across the DACH and broader EMEA regions * Center strengthens collaboration, training and innovation within Europe's life sciences community MINNEAPOLIS and DÜSSELDORF, Germany, Sept. 22, 2026 /CNW/ - Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, today announced the opening of its new Customer Experience Center in Düsseldorf, Germany, a flagship facility designed to bring European customers closer to Bio-Techne's latest innovations and scientific expertise. The new center serves as a regional hub where researchers, biopharmaceutical companies, biotechnology innovators and clinical laboratories can explore integrated technologies and workflows firsthand, helping accelerate scientific discovery, translational research and clinical impact. Located in one of Europe's leading centers for academic research and innovation, the Düsseldorf Customer Experience Center enables customers throughout the Germany, Austria, and Switzerland (DACH) region and the broader Europe, Middle East, and Africa (EMEA) region to engage directly with Bio-Techne scientists, technologies and solutions. The center has been designed to showcase integrated workflows in a single environment, giving researchers the opportunity to evaluate technologies, gain hands-on experience and identify approaches that can advance scientific discovery and improve patient outcomes. Through demonstrations and interactive learning experiences, visitors can explore techniques and applications across protein biology, spatial biology, cell therapy, molecular diagnostics, and analytical instrumentation. Beyond customer engagement, the Düsseldorf center will serve as a regional hub for learning, training, and collaboration. The facility will host workshops, thought leadership events and technical training programs while strengthening Bio-Techne's engagement with universities, research institutes and emerging biotechnology companies throughout the region. Professor Jörg Wischhusen, Ph.D. University Hospital Würzburg, scientific founder CatalYm and co-founder Toleris Biotherapeutics said, "Getting direct access to Bio-Techne's technologies, workflows and scientific experts in one location is an exciting prospect for researchers like us. The ability to evaluate technologies firsthand and experience complete workflows in action should help to make faster and more informed decisions that can accelerate research and development." "Researchers increasingly need partners who can help bridge discovery, translational research and clinical application," said Frank Splettstoesser, Experimental Anesthesiology AG Frede, University Hospital Bonn. "The Düsseldorf Customer Experience Center provides an environment where scientists can learn, collaborate, and explore innovative solutions that address complex biological questions. It demonstrates Bio-Techne's commitment to supporting scientific excellence across Europe." "The opening of our Düsseldorf Customer Experience Center represents a significant investment in the scientific community across Europe," said Kim Kelderman, President and Chief Executive Officer of Bio-Techne. "Our goal is to provide researchers and clinicians with the tools, technologies and expertise they need to answer complex biological questions and improve human health. By creating a destination where scientists can experience innovative techniques firsthand, collaborate with our experts, and evaluate integrated workflows, we are helping accelerate breakthroughs from research to real-world impact." Düsseldorf Mayor Dr. Stephan Keller said, "Bio-Techne's investment in Düsseldorf reflects the strength of our region as a center for life science innovation and international business. We welcome the company's continued expansion and commitment to North Rhine-Westphalia and our city, further reinforcing our strong life sciences ecosystem and collaborative environment that benefits researchers, institutions and businesses alike." The new center also reflects Bio-Techne's commitment to sustainable growth and long-term investment in Europe. Located within a refurbished facility designed with modern energy-efficient features, the site provides convenient access for customers across Germany and the broader region while creating capacity for future expansion as customer needs evolve. By bringing together innovation, expertise and collaboration in a single location, the Düsseldorf Customer Experience Center reinforces Bio-Techne's commitment to empowering scientists with the tools and technologies needed to reach better answers and advance the future of life science research and healthcare. ABOUT BIO-TECHNE Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company headquartered in Minnesota, celebrating 50 years of empowering scientific and diagnostic communities to reach better answers. The company provides high-quality reagents, analytical instruments, and precision diagnostics. Its portfolio is organized into three customer-focused brands: R&D Systems(TM), Bio-Techne Spatial(TM), and Bio-Techne Diagnostics(TM), reflecting the scientific journey from discovery to translational research to clinical decision-making. Bio-Techne operates in 34 locations worldwide and employs more than 3,000 people. In fiscal year 2026, the company generated over $1.2 billion in net sales. Its more than 500,000 products are used globally by academic researchers, biopharmaceutical and biotechnology companies, and clinical diagnostic laboratories. MEDIA CONTACTS Investor Relations David Clair, Vice President [email protected] SOURCE Bio-Techne Corporation
Bio-Techne has achieved validation of its greenhouse gas reduction targets from the Science Based Targets initiative. The life sciences company aims to cut absolute Scope 1 and 2 emissions by 70% by fiscal 2031 from a fiscal 2025 baseline. In fiscal 2026, Bio-Techne reduced market-based Scope 1 and 2 emissions by 49% year-over-year. The company now sources 51% of its electricity from renewable sources after transitioning its Minneapolis headquarters and St Paul GMP facility to renewable power. Bio-Techne also committed that 81% of suppliers by spend will have science-based targets by fiscal 2030. The company completed its first comprehensive Scope 3 emissions inventory during the year. The Minnesota-based company generated over $1.2 billion in net sales in fiscal 2026.
Bio-Techne reported Q2 revenues of $321.2 million, up 1.3% year on year and exceeding analyst expectations by 2%. The life sciences company, which manufactures specialised reagents, instruments, and services for researchers, delivered a strong quarter with solid organic revenue performance. The research tools and consumables sector faces both opportunities and challenges. Whilst emerging fields like synthetic biology and personalised medicine drive demand, companies must navigate high R&D costs, pricing pressures from budget-conscious institutions, and vulnerability to research funding fluctuations. The 10 research tools and consumables stocks tracked collectively beat revenue estimates by 1.7% in Q2. Share prices have risen 6.3% on average since the latest earnings results.
Bio-Techne Corporation reported adjusted earnings per share of 52 cents for the fourth quarter of fiscal 2026, meeting the Zacks Consensus Estimate despite a 1.9% year-over-year decline. GAAP EPS was 35 cents, compared to a loss of 11 cents in the prior-year quarter. Fourth-quarter net sales reached $321.2 million, up 1% year over year on a reported basis and 3% organically, surpassing the consensus estimate by 1.26%. Full-year revenues were $1.22 billion, remaining flat from fiscal 2025. The Protein Sciences segment generated revenues of $231.2 million, up 2% year over year. Diagnostics and Spatial Biology revenues remained roughly flat at $90.1 million. Gross margin expanded 310 basis points to 65.8%. The company generated operating income of $74.3 million, compared to an operating loss of $23.9 million in the year-ago quarter. Following the announcement, shares edged up 0.1% to close at $72.23.